---
title: List of Policies for Pharmacovigilance – P109
description: Explore key Pharmacovigilance policies covering drug safety, adverse event reporting, compliance, risk management, and patient protection.
---

[Policy ](https://blog.fhyzics.net/policy)

# [List of Policies for Pharmacovigilance – P109](https://blog.fhyzics.net/policy/list-of-policies-for-pharmacovigilance-p109)

 Written by [Venkadesh Narayanan](https://blog.fhyzics.net/policy/author/venkadesh-narayanan) | May 18, 2026 11:38:51 AM

The “List of Policies for Pharmacovigilance” provides a comprehensive framework for monitoring, assessing, and managing the safety of pharmaceutical products throughout their lifecycle. These policies help healthcare and pharmaceutical organizations ensure patient safety, regulatory compliance, and effective risk management related to medicinal products. The collection typically includes policies related to adverse event reporting, signal detection, risk evaluation, safety data management, case processing, product safety monitoring, regulatory submissions, medical review, and safety communication. It also covers areas such as pharmacovigilance audits, vendor oversight, data privacy, quality assurance, literature monitoring, training, business continuity, and compliance with global health authority requirements. Implementing well-defined pharmacovigilance policies enables organizations to identify and mitigate drug-related risks, maintain accurate safety records, improve regulatory reporting, and strengthen public trust in healthcare products. These documents serve as operational guidelines for pharmacovigilance teams, medical affairs professionals, regulatory personnel, clinical researchers, and healthcare organizations involved in drug safety management.    
  

1. P109-01 Pharmacovigilance Governance Policy  
2. P109-02 Adverse Event Reporting Policy  
3. P109-03 Serious Adverse Event Management Policy  
4. P109-04 Signal Detection and Management Policy  
5. P109-05 Risk Management Policy  
6. P109-06 Safety Data Collection Policy  
7. P109-07 Individual Case Safety Report Processing Policy  
8. P109-08 Product Safety Monitoring Policy  
9. P109-09 Regulatory Reporting Policy  
10. P109-10 Periodic Safety Update Report Policy  
11. P109-11 Benefit-Risk Assessment Policy  
12. P109-12 Medical Review Policy  
13. P109-13 Literature Monitoring Policy  
14. P109-14 Safety Database Management Policy  
15. P109-15 Pharmacovigilance Audit Policy  
16. P109-16 Quality Assurance in Pharmacovigilance Policy  
17. P109-17 Pharmacovigilance Training Policy  
18. P109-18 Vendor Oversight Policy  
19. P109-19 Data Privacy and Confidentiality Policy  
20. P109-20 Case Intake and Triage Policy  
21. P109-21 Product Complaint Handling Policy  
22. P109-22 Medication Error Reporting Policy  
23. P109-23 Pregnancy Exposure Reporting Policy  
24. P109-24 Safety Communication Policy  
25. P109-25 Regulatory Inspection Readiness Policy  
26. P109-26 Pharmacovigilance Documentation Policy  
27. P109-27 Record Retention and Archiving Policy  
28. P109-28 Global Safety Compliance Policy  
29. P109-29 Clinical Trial Safety Reporting Policy  
30. P109-30 Post-Marketing Surveillance Policy  
31. P109-31 Signal Escalation Policy  
32. P109-32 Corrective and Preventive Action Policy  
33. P109-33 Pharmacovigilance System Master File Policy  
34. P109-34 Third-Party Service Provider Policy  
35. P109-35 Information Security Policy  
36. P109-36 Business Continuity Policy  
37. P109-37 Safety Labeling Update Policy  
38. P109-38 Risk Minimization Measures Policy  
39. P109-39 Pharmacovigilance Compliance Monitoring Policy  
40. P109-40 Digital Safety Reporting Policy  
41. P109-41 Social Media Monitoring Policy  
42. P109-42 Patient Support Program Safety Policy  
43. P109-43 Healthcare Professional Communication Policy  
44. P109-44 Aggregate Reporting Policy  
45. P109-45 Safety Metrics and Reporting Policy  
46. P109-46 Escalation and Crisis Management Policy  
47. P109-47 Pharmacovigilance Inspection Management Policy  
48. P109-48 Global Safety Data Exchange Policy  
49. P109-49 Continuous Improvement in Pharmacovigilance Policy  
50. P109-50 Pharmacovigilance Governance Review Policy 

[View full post](https://blog.fhyzics.net/policy/list-of-policies-for-pharmacovigilance-p109)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Venkadesh Narayanan"
  },
  "dateModified" : "2026-05-21T06:45:11.184Z",
  "datePublished" : "2026-05-18T11:38:51Z",
  "headline" : "List of Policies for Pharmacovigilance – P109",
  "image" : {
    "@type" : "ImageObject",
    "height" : 500,
    "url" : "https://3112120.fs1.hubspotusercontent-na1.net/hubfs/3112120/List%20of%20Policies%20for%20Pharmacovigilance%20%E2%80%93%20P109.png",
    "width" : 1000
  },
  "mainEntityOfPage" : "https://blog.fhyzics.net/policy/list-of-policies-for-pharmacovigilance-p109",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Policy"
  }
}
```